Lombard Odier Transatlantic’s Teva Pharmaceuticals TEVA Stock Holding History

Lombard Odier Transatlantic’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-1,500	Closed	-$75K	–	135
2016 Q2	$75K	Hold	1,500	–	–	0.08%	71
2016 Q1	$80K	Hold	1,500	–	–	0.08%	74
2015 Q4	$98K	Hold	1,500	–	–	0.08%	74
2015 Q3	$85K	Hold	1,500	–	–	0.09%	65
2015 Q2	$89K	Hold	1,500	–	–	0.07%	73
2015 Q1	$93K	Hold	1,500	–	–	0.07%	85
2014 Q4	$86K	Buy	+1,500	New	+$83.6K	0.08%	77

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lombard Odier Transatlantic's TEVA Position: Q3 2016 in Review

Lombard Odier Transatlantic sold out of Teva Pharmaceuticals (TEVA) in Q3 2016, closing a stake of 1,500 shares — an estimated $75K sold.

Lombard Odier Transatlantic first reported a position in TEVA in Q4 2014 and held it in 7 quarters. The position peaked at $98K in Q4 2015. 795 funds tracked by Wall St. Rank hold TEVA as of Q3 2016.

Lombard Odier Transatlantic reported no remaining Teva Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Lombard Odier Transatlantic sold 1,500 Teva Pharmaceuticals shares in Q3 2016, an estimated $75K.
Lombard Odier Transatlantic first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 7 quarters.
Lombard Odier Transatlantic's Teva Pharmaceuticals position peaked at $98K in Q4 2015.
795 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2016.

Based on Lombard Odier Transatlantic's 13F filing for Q3 2016, filed 14 Nov 2016.